PYROS PHARMS
PharmaPYROS PHARMS is a pharmaceutical company focused on Neurology. Key products include VIGAFYDE.
PYROS PHARMS's Key Drugs
PYROS PHARMS's core commercial portfolio centers on VIGPODER, VIGAFYDE, spanning Neurology — its most strategically important drugs approved in the last 15 years.
PYROS PHARMS's Recent FDA Approvals
New NDA/BLA approvals for PYROS PHARMS over the last two years — novel drugs only, excluding generics and label supplements.
PYROS PHARMS's Therapeutic Areas
PYROS PHARMS's approved drugs and pipeline span 1 therapeutic area, led by Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
PYROS PHARMS's Top Competitors
PYROS PHARMS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
PYROS PHARMS Pipeline Snapshot
Active clinical trials for PYROS PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • VIGPODER leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling